Bio Place

Latest Medical, Biological, and Genomic News!


Corvus reports complete responses in T cell lymphoma

"CRVS’ lead candidate is CP-818, an oral ITK inhibitor...currently being evaluated as a single-agent therapy in a phase I/Ib study...The company reported two complete responses (CR), one nodal CR and three partial responses (PR)."
Yahoo!Zacks Img:Corvus
2023-05-16 11:57:49